Hospital
Munson Healthcare Grayling
Munson Healthcare Grayling was paid $13.93M by Medicaid between Jan 2018 and Dec 2024, across 249 billing codes. Its largest line is 99285, emergency room visit (most serious) — 17% of everything it billed.
33Billing provider infoMUNSON HEALTHCARE GRAYLING
GRAYLING, MI 49738
GRAYLING, MI 49738
33aNPI1083010953assigned 11/05/2014
33bProvider typeRural Acute Care Hospital
28Total paid$13.93M
24GClaims610,576
24DCodes billed249
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in Michigan
Rank by total paid#3 of 5
Median peer was paid$13.93M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 97,101 | $2.02M | |
| 2019 | 95,085 | $1.95M | |
| 2020 | 74,861 | $1.69M | |
| 2021 | 93,335 | $2.30M | |
| 2022 | 94,332 | $2.26M | |
| 2023 | 90,298 | $2.07M | |
| 2024incomplete | 65,564 | $1.65M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 7,638 | 7,173 | $2.31M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 15,942 | 15,151 | $1.93M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 9,395 | 8,974 | $1.73M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.4% | 9,481 | 8,643 | $886K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 3,591 | 3,446 | $509K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.2% | 6,197 | 6,049 | $441K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.5% | 4,017 | 3,382 | $349K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.2% | 9,365 | 7,772 | $300K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.0% | 4,962 | 4,349 | $276K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.0% | 15,886 | 4,664 | $273K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.9% | 12,478 | 4,613 | $259K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 7,772 | 6,674 | $246K |
237 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 2,755 | $243K |
| 71045 | Radiologic examination, chest; single view | 1.7% | 6,353 | $236K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.3% | 15,552 | $188K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 889 | $184K |
| 59025 | Fetal non-stress test | 1.3% | 2,113 | $181K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.3% | 1,775 | $174K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 4,303 | $155K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,234 | $131K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,646 | $120K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,015 | $118K |
| 80061 | Lipid panel | <1% | 8,069 | $113K |
| G0378 | Hospital observation service, per hour | <1% | 623 | $103K |
| 76801 | <1% | 1,693 | $100K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,709 | $96K |
| 86900 | <1% | 4,183 | $95K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,526 | $90K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,404 | $88K |
| 76830 | Ultrasound, transvaginal | <1% | 1,455 | $85K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,246 | $81K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 941 | $81K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,740 | $80K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 4,945 | $73K |
| 80053 | Comprehensive metabolic panel | <1% | 27,027 | $67K |
| 73564 | <1% | 1,982 | $63K | |
| 97162 | <1% | 1,255 | $61K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,386 | $61K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 963 | $58K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 38,085 | $58K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,599 | $56K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 630 | $49K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,033 | $43K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,450 | $41K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 205 | $39K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,164 | $36K |
| 73610 | <1% | 1,926 | $36K | |
| 73030 | <1% | 1,822 | $35K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 7,935 | $33K |
| 36415 | Collection of venous blood by venipuncture | <1% | 25,750 | $33K |
| 97161 | <1% | 689 | $29K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,562 | $28K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 313 | $27K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,584 | $27K |
| 73630 | <1% | 1,869 | $27K | |
| 73130 | <1% | 1,820 | $27K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,422 | $26K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,601 | $25K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,905 | $23K |
| 74018 | <1% | 948 | $22K | |
| 73110 | <1% | 1,166 | $20K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,181 | $20K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,591 | $20K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,875 | $18K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 205 | $18K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 102 | $16K |
| 86780 | <1% | 2,367 | $15K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 51 | $15K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,456 | $15K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 660 | $14K |
| 82607 | <1% | 2,265 | $14K | |
| 81025 | <1% | 9,573 | $13K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,126 | $13K |
| 84439 | <1% | 3,414 | $13K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,608 | $12K |
| 82728 | <1% | 2,025 | $11K | |
| 72110 | <1% | 443 | $11K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 37 | $10K |
| 86803 | <1% | 1,717 | $10K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 866 | $8K |
| 85027 | <1% | 4,071 | $8K | |
| 87653 | <1% | 469 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 303 | $8K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 25 | $8K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 865 | $7K |
| 71271 | <1% | 138 | $7K | |
| 84702 | <1% | 1,713 | $7K | |
| 86762 | <1% | 1,243 | $7K | |
| 87340 | <1% | 1,779 | $7K | |
| 73502 | <1% | 413 | $7K | |
| 86787 | <1% | 1,273 | $7K | |
| 81001 | <1% | 18,063 | $7K | |
| 87150 | <1% | 486 | $7K | |
| 87186 | <1% | 2,709 | $7K | |
| 87077 | <1% | 2,781 | $6K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 18 | $6K |
| 87081 | <1% | 2,569 | $6K | |
| 93971 | <1% | 99 | $6K | |
| 94726 | <1% | 174 | $5K | |
| 82746 | <1% | 874 | $5K | |
| 83550 | <1% | 1,489 | $5K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 458 | $5K |
| 83735 | <1% | 8,365 | $5K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 311 | $5K |
| 83540 | <1% | 1,925 | $5K | |
| 76642 | <1% | 116 | $5K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 18 | $5K |
| 96376 | <1% | 2,894 | $5K | |
| 94060 | <1% | 38 | $5K | |
| 85610 | <1% | 8,020 | $5K | |
| 81002 | <1% | 2,992 | $4K | |
| 86850 | <1% | 3,910 | $4K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 197 | $4K |
| 82570 | <1% | 1,908 | $4K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 202 | $4K |
| 74022 | <1% | 673 | $4K | |
| 93017 | <1% | 189 | $4K | |
| 83880 | <1% | 1,347 | $4K | |
| 86140 | <1% | 3,194 | $3K | |
| C9399 | Unclassified drugs or biologicals | <1% | 123 | $3K |
| 96367 | <1% | 116 | $3K | |
| 82043 | <1% | 1,373 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 323 | $3K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 25 | $3K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 153 | $3K |
| 87807 | <1% | 1,081 | $3K | |
| 76775 | <1% | 63 | $3K | |
| 76536 | <1% | 52 | $2K | |
| 82950 | <1% | 1,084 | $2K | |
| 80306 | <1% | 1,414 | $2K | |
| 82947 | <1% | 1,177 | $2K | |
| 80076 | <1% | 4,173 | $2K | |
| 87088 | <1% | 843 | $2K | |
| 73100 | <1% | 45 | $2K | |
| 97163 | <1% | 39 | $2K | |
| 87070 | <1% | 812 | $2K | |
| 85652 | <1% | 2,718 | $2K | |
| 97116 | <1% | 209 | $2K | |
| 83690 | <1% | 6,482 | $1K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 686 | $1K |
| 72100 | <1% | 36 | $1K | |
| 87507 | <1% | 15 | $1K | |
| 72141 | <1% | 12 | $1K | |
| 86901 | <1% | 4,182 | $1K | |
| 73560 | <1% | 41 | $1K | |
| 73080 | <1% | 86 | $1K | |
| 82248 | <1% | 655 | $1K | |
| 87210 | <1% | 725 | $1K | |
| 86038 | <1% | 225 | $1K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 86 | $889.56 |
| 87205 | <1% | 815 | $872.52 | |
| 73140 | <1% | 29 | $766.22 | |
| 72070 | <1% | 25 | $756.53 | |
| 82077 | <1% | 1,988 | $715.56 | |
| 85730 | <1% | 5,332 | $712.16 | |
| 97035 | <1% | 122 | $670.96 | |
| 82565 | <1% | 426 | $667.30 | |
| 82150 | <1% | 1,154 | $603.85 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 13 | $588.48 |
| 82962 | <1% | 2,119 | $540.98 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,011 | $530.54 |
| 77065 | Tomosynthesis, mammo | <1% | 12 | $528.72 |
| 93225 | <1% | 12 | $483.72 | |
| 87631 | <1% | 18 | $436.81 | |
| 87634 | <1% | 47 | $417.00 | |
| 97165 | <1% | 15 | $406.71 | |
| 84153 | <1% | 47 | $404.44 | |
| 73090 | <1% | 43 | $393.62 | |
| 84100 | <1% | 633 | $308.44 | |
| 84403 | <1% | 29 | $281.85 | |
| 80074 | <1% | 13 | $239.44 | |
| 73590 | <1% | 39 | $238.20 | |
| 85379 | <1% | 1,692 | $230.18 | |
| 83970 | <1% | 12 | $177.85 | |
| 84481 | <1% | 26 | $175.00 | |
| 87040 | <1% | 1,693 | $148.36 | |
| 83605 | <1% | 4,455 | $144.41 | |
| 83001 | <1% | 24 | $143.47 | |
| 82105 | <1% | 37 | $122.13 | |
| 84550 | <1% | 101 | $106.18 | |
| 71101 | <1% | 14 | $101.71 | |
| 12001 | <1% | 39 | $100.76 | |
| 84484 | <1% | 5,734 | $94.27 | |
| 86431 | <1% | 41 | $90.89 | |
| 84460 | <1% | 42 | $88.24 | |
| 86376 | <1% | 13 | $82.00 | |
| 86704 | <1% | 13 | $71.49 | |
| 84703 | <1% | 366 | $66.83 | |
| 86039 | <1% | 12 | $66.40 | |
| 88304 | <1% | 42 | $59.22 | |
| 84156 | <1% | 48 | $53.71 | |
| 80179 | <1% | 1,199 | $51.31 | |
| 80143 | <1% | 1,231 | $51.31 | |
| 86308 | <1% | 26 | $46.34 | |
| 83615 | <1% | 43 | $43.23 | |
| 90715 | <1% | 303 | $32.25 | |
| 84450 | <1% | 13 | $29.53 | |
| 82550 | <1% | 25 | $29.38 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,491 | $15.90 |
| 85018 | <1% | 12 | $11.04 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,904 | $3.34 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 1,601 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 3,240 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,887 | $0.00 |
| 82803 | 0% | 92 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 1,659 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 3,870 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 4,054 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 87 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,151 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 2,434 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 1,232 | $0.00 |
| 94760 | 0% | 1,578 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 257 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 986 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 7,096 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 63 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 264 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 227 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 50 | $0.00 |
| A9270 | Non-covered item or service | 0% | 57 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 115 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 158 | $0.00 |
| 96368 | 0% | 27 | $0.00 | |
| 94761 | 0% | 120 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 29 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 28 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 404 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 2,408 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 9,332 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,545 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 3,390 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 780 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 14 | $0.00 |
| 94664 | 0% | 433 | $0.00 | |
| 94729 | 0% | 128 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 433 | $0.00 |
| 80305 | 0% | 15 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 261 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 72 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 159 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 158 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 71 | $0.00 |
| 93226 | 0% | 12 | $0.00 | |
| 94150 | 0% | 22 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 19 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 27 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 13 | $0.00 |
| 82375 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKORTH-WHITE, KIRSTEN (PRESIDENT/CEO EAST REIGON)
Parent organizationMUNSON HEALTHCARE
| Provider | Location | Paid |
|---|---|---|
| Munson Healthcare Manistee Hospital | Manistee, MI | $9.52M |
| Munson Healthcare Charlevoix Hospital | Charlevoix, MI | $8.26M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.